Diligence memo · auto-generated · as of July 2, 2026

Integrated Diagnostics, Inc.

Integrated Diagnostics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Integrated Diagnostics, Inc. operates in Biotechnology, based in SEATTLE.

Sub-sector tags: medical-devices.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Integrated Diagnostics, Inc. has raised $45M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $32M on 2014-04-25.

Most recent recorded round closed around 2016-11-23.

Valuation (modeled)modeled

Provath models Integrated Diagnostics, Inc. at approximately $242M (range $12M–$932M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.30× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 43 months.

Last raise 9.6 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 5.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 80% of Biotechnology peers (4293 compared).

Modeled value ranks above 74% of those peers.

Closest niche peers: Liquid BioScience, Inc., Amphivena Therapeutics, Inc., Tracon Pharmaceuticals, Inc., Tetra Discovery Partners, Inc., ECM Therapeutics, Inc..

Peoplefiled

15 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.